Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence

被引：0
|
作者：
Rosa Escudero-Sanchez
Antonio Ramos-Martínez
Antonio F. Caballero-Bermejo
Beatriz Díaz-Pollán
Guillermo Ruiz-Carrascoso
María Olmedo Samperio
Patricia Muñoz García
Paloma Merino Amador
Fernando González Romo
Oriol Martín Segarra
Gema Navarro Jiménez
Laura del Campo Albendea
Alfonso Muriel García
Javier Cobo
机构：
[1] Ramon y Cajal University Hospital,Infectious Disease Department
[2] Instituto de Salud Carlos III (IRYCIS),Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC)
[3] Instituto de Salud Carlos III,Internal Medicine Department
[4] University Hospital Puerta de Hierro-Majadahonda,Pharmacology Department
[5] University Hospital Puerta de Hierro-Majadahonda,Infectious Diseases Unit, Internal Medicine Department
[6] La Paz University Hospital,Microbiology Department
[7] La Paz Institute for Health Research (IdiPAZ),Microbiology and Infectious Disease Department
[8] La Paz University Hospital,Microbiology Department
[9] Gregorio Marañón University Hospital,Infectious Disease Department
[10] Clínico San Carlos University Hospital,Biostatistics Unit
[11] Fundación Alcorcon University Hospital,undefined
[12] University Hospital Ramon y Cajal,undefined
[13] Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP),undefined
[14] Universidad de Alcalá,undefined
来源：
European Journal of Clinical Microbiology & Infectious Diseases | 2024年 / 43卷
关键词：
Bezlotoxumab; infection; Recurrence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：533 / 540
页数：7
相关论文
共 50 条
  • [41] Comparing Recurrence Rates of Clostridioides difficile Infection in Patients With Inflammatory Bowel After Low, Medium, and High Doses of Oral Vancomycin for the Initial Episode of CDI
    Khan, Adnan
    Mitsuhashi, Shuji
    Chauhan, Kashyap
    Dimarino, Michael
    Ross, Heather M.
    Zhang, Peter
    Schafer, Michelle
    Mujumdar, Sahaj
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S760 - S760
  • [42] Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
    de la Villa, Sofia
    Herrero, Sergio
    Munoz, Patricia
    Rodriguez, Carmen
    Valerio, Maricela
    Reigadas, Elena
    Alvarez-Uria, Ana
    Alcala, Luis
    Marin, Mercedes
    Olmedo, Maria
    Kestler, Martha
    Chamorro, Esther
    Bouza, Emilio
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (02):
  • [43] Real World Experience of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Mayo Clinic Experience
    Sehgal, Kanika
    Tariq, Raseen
    Pardi, Darrell S.
    Khanna, Sahil
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S141 - S141
  • [44] Baseline stool toxin concentration is associated with risk of recurrence in children with Clostridioides difficile infection
    Sandora, Thomas J.
    Kociolek, Larry K.
    Williams, David N.
    Daugherty, Kaitlyn
    Geer, Christine
    Cuddemi, Christine
    Chen, Xinhua
    Xu, Hua
    Savage, Timothy J.
    Banz, Alice
    Garey, Kevin W.
    Gonzales-Luna, Anne J.
    Kelly, Ciaran P.
    Pollock, Nira R.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2023, 44 (09): : 1403 - 1409
  • [45] Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience
    Pettit, Natasha N.
    Lew, Alison K.
    Nguyen, Cynthia T.
    Bell, Elizabeth
    Lehmann, Christopher J.
    Pisano, Jennifer
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2024, 45 (11) : 1286 - 1292
  • [46] Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection
    Saha, Srishti
    Mara, Kristin
    Pardi, Darrell S.
    Khanna, Sahil
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1706 - E1712
  • [47] Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies
    Daniele Roberto Giacobbe
    Silvia Dettori
    Stefano Di Bella
    Antonio Vena
    Guido Granata
    Roberto Luzzati
    Nicola Petrosillo
    Matteo Bassetti
    Infectious Diseases and Therapy, 2020, 9 : 481 - 494
  • [48] Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
    Dubberke, Erik R.
    Gerding, Dale N.
    Kelly, Ciaran P.
    Garey, Kevin W.
    Rahav, Galia
    Mosley, Audrey
    Tipping, Robert
    Dorr, Mary Beth
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):
  • [49] Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis
    Escudero-Sanchez, Rosa
    Rubio Martin, Elena
    Vizcarra, Pilar
    Braojos Sanchez, Francisco
    Diaz Gago, Alvaro
    Del Campo Albendea, Laura
    Muriel, Alfonso
    Halperin, Ana
    Ponce Alonso, Manuel
    Moreno Guillen, Santiago
    Cobo, Javier
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (03) : 823 - 827
  • [50] Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection- An observational cohort study
    Hernando-Gozalo, Marcos
    Rescalvo-Casas, Carlos
    Seijas-Pereda, Laura
    Cuadros-Gonzalez, Juan
    Perez-Tanoira, Ramon
    HELIYON, 2024, 10 (10)
12345